<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346925</article-id>
      <article-id pub-id-type="pmc">3875975</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131699</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Propranolol for treatment of infantile hemangiomas<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Tratamento de hemangiomas infantis com propranolol</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de Melo</surname>
            <given-names>Juliana Nakano</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rotter</surname>
            <given-names>Anita</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rivitti-Machado</surname>
            <given-names>Maria Cec&#xED;lia</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Zilda Najjar Prado</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, PhD in Dermatology from the University of S&#xE3;o Paulo (USP) - Medical
Manager at Abbott Laboratories - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, Assistant doctor - Pediatric Dermatology, Teaching Hospital,
University of S&#xE3;o Paulo (HC-FMUSP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff03"><label>3</label> MD, Master's degree in Dermatology from the University of S&#xE3;o Paulo
(USP) - Assistant doctor - Pediatric Dermatology, Teaching Hospital, University of S&#xE3;o
Paulo (HC-FMUSP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff04"><label>4</label> MD, PhD in Dermatology from the University of S&#xE3;o Paulo (USP). Head of
Pediatric Dermatology Unit, Teaching Hospital, University of S&#xE3;o Paulo (HCFMUSP) - S&#xE3;o
Paulo (SP), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Juliana Nakano de Melo, Av. Rep&#xFA;blica do L&#xED;bano, 460 -
Ibirapuera - 004502-000 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>julinakano@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>220</fpage>
      <lpage>223</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>2</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Infantile hemangioma is the most common vascular tumor in early childhood.
Propranolol has been successfully used recently in a limited number of children with
Infantile hemangioma. We present 6 cases of Infantile hemangioma, at a single
dermatological center, which responded to oral propranolol with good results.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>O hemangioma da inf&#xE2;ncia &#xE9; o tumor vascular mais comum nessa faixa et&#xE1;ria. Mais
recentemente, propranolol oral tem sido usado com sucesso em um n&#xFA;mero limitado de
crian&#xE7;as com hemangioma da inf&#xE2;ncia. N&#xF3;s apresentamos 6 casos de hemangioma da
inf&#xE2;ncia, provenientes de um &#xFA;nico centro dermatol&#xF3;gico, que apresentaram boa
resposta ao tratamento com propranolol oral.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Hemangioma</kwd>
        <kwd>Propranolol</kwd>
        <kwd>Vascular neoplasms</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Infantile hemangiomas (IH) are the most common benign tumors in early childhood and
usually have a non-harmful clinical course.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Most hemangiomas become evident within the first few weeks of life
and may be subtle at birth.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> About 10%
of IH develop complications and require treatment, especially those located in the
periocular, airway and perineal areas.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Systemic corticosteroids have been the mainstay of complicated IH
treatment. Recently, propranolol has shown excellent response in proliferative IH and
has become an additional therapeutic option.<sup><xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
      <p>We present 6 cases of IH, including subtypes such as PHACES syndrome, "beard hemangioma"
and Cyrano's hemangioma which were successfully treated with oral propranolol at 2mg/kg
per day every 12 hours. </p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <sec>
        <title>1.1. Case 1 </title>
        <p>A 2-month-old girl born at term was referred to our clinic with a protuberant
hemangioma on face, impinging on the superior right eyelid (<xref ref-type="fig" rid="f01">Figure 1A</xref>). Propranolol was introduced, and the lesion reduced in
size and had largely healed within 6 months (<xref ref-type="fig" rid="f01">Figure
1B</xref>). This infant had an eye examination and impairment of visual function,
strabismus, astigmatism or amblyopia were ruled out. At the age of 9 months, she
developed a red telangiectatic macula in the previous hemangioma area (<xref ref-type="fig" rid="f01">Figure 1C</xref>). It is being planned to taper off
propranolol after the child is 1 year and 6 months of age. </p>
        <fig id="f01" orientation="portrait" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>
<bold>A.</bold> Hemangioma in superior right eyelid area; <bold>B.</bold> After
6 months of propranolol; <bold>C.</bold> Residual macula after 9 months of
treatment</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g01"/>
        </fig>
      </sec>
      <sec>
        <title>1.2. Case 2 </title>
        <p>A 5-month-old boy born at term was referred to our clinic with a left arm hemangioma
of 8.0 x 6.0 cm, presenting a lateral ulceration measuring 1.0 x 1.0 cm (<xref ref-type="fig" rid="f02">Figure 2A</xref>). Despite management with gentamicin
ointment dressings, the ulceration failed to heal. One month later it became larger
and started to bleed, causing pain and discomfort to the infant (<xref ref-type="fig" rid="f02">Figure 2B</xref>). Propranolol was initiated at the age of 6 months and
there was a significant reduction in size of the ulcer within a week. Seven months
later, the deep component was much reduced and the superficial part healed (<xref ref-type="fig" rid="f02">Figure 2C</xref>). It is planned to wean off propranolol
when the child is at least 1 year and 6 months of age.</p>
        <fig id="f02" orientation="portrait" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>
<bold>A.</bold> A 5-month old boy with hemangioma on his left arm;
<bold>B.</bold> Spontaneous ulceration at 6 month age; <bold>C.</bold>
Regression of hemangioma after 7 months of propranolol treatment</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g02"/>
        </fig>
      </sec>
      <sec>
        <title>1.3. Case 3 </title>
        <p>A 2-month old girl born at term was referred for management of a nasal IH, also known
as "Cyrano's hemangioma" (<xref ref-type="fig" rid="f03">Figure 3A</xref>).
Propranolol was started and there was significant reduction in size and color of
lesion within one month (<xref ref-type="fig" rid="f03">Figure 3B</xref>). She is at
the sixth month of oral propranolol treatment, and the lesion is still improving
(<xref ref-type="fig" rid="f03">Figure 3C</xref>). </p>
        <fig id="f03" orientation="portrait" position="float">
          <label>FIGURE 3</label>
          <caption>
            <p>
<bold>A.</bold> Nasal hemangioma in 2-month-old girl; <bold>B.</bold>
Significant decrease in size and color after one month of oral propranolol;
<bold>C.</bold> At the sixth month of treatment, the lesion continues to
improve with oral propranolol</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g03"/>
        </fig>
      </sec>
      <sec>
        <title>1.4. Case 4 </title>
        <p>A 6-month old girl born at 35 weeks, was referred with a combined superficial and
deep segmental IH (S3 and S4 involvement of PHACES syndrome) (<xref ref-type="fig" rid="f04">Figure 4A</xref>). Recently she underwent a successful cardiac surgery
for correction of an interventricular wall defect. We decided to investigate
neurological and ophthalmological abnormalities, suspecting PHACES syndrome, and she
was diagnosed with strabismus. We started propranolol at 8 months, with a rapid
improvement of the hemangioma and strabismus within a month (<xref ref-type="fig" rid="f04">Figure 4B</xref>). She was treated with propranolol until 1 year and 8
months of age, and four months later, the hemangioma remains without signs of
recurrence (<xref ref-type="fig" rid="f04">Figure 4C</xref>). </p>
        <fig id="f04" orientation="portrait" position="float">
          <label>FIGURE 4</label>
          <caption>
            <p>
<bold>A.</bold> PHACES Syndrome before treatment; <bold>B.</bold> Evident
improve of hemangioma and strabismus after one month of treatment;
<bold>C.</bold> No signs of recurrence 4 months after stopping
propranolol</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g04"/>
        </fig>
      </sec>
      <sec>
        <title>1.5. Case 5 </title>
        <p>A 2-month-old girl born at 33 weeks was referred for treatment of a large facial
hemangioma, with total occlusion of the left eye (<xref ref-type="fig" rid="f05">Figure 5A</xref>). Ophthalmological examination revealed no abnormalities, and
propranolol was introduced at this age. The lesion reduced in size and had largely
healed in 2 months (<xref ref-type="fig" rid="f05">Figure 5B</xref>). She received
propranolol until 1 year and 9 months of age, and 8 months later she remains free of
the hemangioma, with only a few residual telangiectasias (<xref ref-type="fig" rid="f05">Figure 5C</xref>). </p>
        <fig id="f05" orientation="portrait" position="float">
          <label>FIGURE 5</label>
          <caption>
            <p>
<bold>A.</bold> Large facial hemangioma before treatment; <bold>B.</bold> After
2 months of oral propranolol; <bold>C.</bold> Residual telangiectasias 8 months
after end of therapy</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g05"/>
        </fig>
      </sec>
      <sec>
        <title>1.6. Case 6 </title>
        <p>A 5-month-old girl born at term was referred for investigation of a "beard
hemangioma", which was progressively increasing in size, causing deformity in the
neck area (<xref ref-type="fig" rid="f06">Figure 6A</xref>). There was no difficulty
in breathing or hoarseness, but radiological exams were performed to rule out
internal hemangiomas, such as in the subglottic area. Ultrasound revealed parotid
involvement of hemangioma, and the otorhinolaryngological examination was otherwise
normal. We started oral propranolol at this age, and 2 months later she showed great
response with decrease of neck volume and of the hemangioma located over the
mandibular area (<xref ref-type="fig" rid="f06">Figure 6B</xref>). Its is planned to
wean off propranolol when she is 1 year and 6 months of age. </p>
        <fig id="f06" orientation="portrait" position="float">
          <label>FIGURE 6</label>
          <caption>
            <p>
<bold>A.</bold> &#x201C;Beard hemangioma&#x201D; causing neck deformity; <bold>B.</bold>
Reduction of neck volume after 2 months of therapy</p>
          </caption>
          <graphic xlink:href="abd-88-06-s1-0220-g06"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Infantile hemangioma has an incidence of up to 10% in white infants, occurring more
frequently in premature and female infants.<sup><xref ref-type="bibr" rid="r04">4</xref></sup> Of our 6 cases, 5 were girls and 2 were premature, consistent with
published data.<sup><xref ref-type="bibr" rid="r05">5</xref></sup> The mechanisms that
control involution of IH are poorly understood; new evidence shows that apoptosis may be
partially responsible.<sup><xref ref-type="bibr" rid="r06">6</xref></sup> L&#xE9;aute-Labr&#xE8;ze
<italic>et al</italic>
<sup><xref ref-type="bibr" rid="r03">3</xref></sup> recently reported a surprising
response to treatment of IH with propranolol, which was confirmed by other
studies.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>The therapeutic effect of propranolol in infantile hemangiomas is probably secondary to
3 different mechanisms: <bold>1) </bold>vasoconstriction; <bold>2) </bold>decreased
expression of vascular endothelial growth factor (VEGF); <bold>3) </bold>triggering of
apoptosis of capillary endothelial cells.<sup><xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>Few serious side effects and no deaths are described<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Prior to therapeutic and clinical cardiologic evaluation,
echocardiogram and electrocardiogram were performed. Serious side effects include
bronchospasms in asthmatic patients, hypoglycemia and restless sleep. We recommended to
stop the treatment during episodes of bronchiolitis. We did not observe any side effects
of beta-blockers. </p>
      <p>In our cases, there was almost immediate cessation of proliferation of hemangioma in
every patient, leading to considerable shortening of the natural course of the
lesion.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> The initial dose of
propranolol was 1mg/kg per day for the first week and then increased up to the maximum
dosage of 2mg/kg per day. </p>
      <p>These cases showed that propranolol was equally effective for the treatment of IHs in
both sexes and in segmental and non segmental IHs. Ulcerating IH also showed a dramatic
improvement. </p>
      <p>We acknowledge that the number of patients in this study is limited, and data of more
patients are needed before definitive conclusions can be reached. However, in this
observational study, oral propranolol 2 mg/kg/day was a well-tolerated and effective
treatment for IHs.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work performed at the Pediatric Dermatology Unit, Teaching Hospital, School of
Medicine, University of S&#xE3;o Paulo (HC-FMUSP) - S&#xE3;o Paulo (SP), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xE9;aut&#xE9;-Labr&#xE8;ze</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Prey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ezzedine</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Infantile haemangioma: Part II. Risks, complications and
treatment</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2011</year>
          <volume>25</volume>
          <fpage>1254</fpage>
          <lpage>1260</lpage>
          <pub-id pub-id-type="pmid">21569113</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drolet</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Esterly</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Frieden</surname>
              <given-names>IJ</given-names>
            </name>
          </person-group>
          <article-title>Hemangiomas in children</article-title>
          <source>N Engl J Med</source>
          <year>1999</year>
          <volume>341</volume>
          <fpage>173</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">10403856</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xE9;aut&#xE9;-Labr&#xE8;ze</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dumas de la Roque</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hubiche</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Boralevi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thambo</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ta&#xEF;eb</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Propranolol for severe hemangiomas of infancy</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>358</volume>
          <fpage>2649</fpage>
          <lpage>2651</lpage>
          <pub-id pub-id-type="pmid">18550886</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garzon</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Drolet</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Baselga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chamlin</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Haggstrom</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Horii</surname>
              <given-names>K</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Comparison of infantile hemangiomas in preterm and term infants: a
prospective study</article-title>
          <source>Arch Dermatol</source>
          <year>2008</year>
          <volume>144</volume>
          <fpage>1231</fpage>
          <lpage>1232</lpage>
          <pub-id pub-id-type="pmid">18794478</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermans</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Boezeman</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Van de Kerkhof</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Rieu</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Van der Vleuten</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Differences between ulcerated and non-ulcerated hemangioma, a
retrospective study of 456 patients</article-title>
          <source>Eur J Dermatol</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>152</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">19106042</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Razon</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kr&#xE4;ling</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Mulliken</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Bischoff</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Increased apoptosis coincides with onset of involution in infantile
hemangioma</article-title>
          <source>Microcirculation</source>
          <year>1998</year>
          <volume>5</volume>
          <fpage>189</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="pmid">9789259</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawley</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Siegfried</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Propranolol treatment for hemangioma of infancy: risks and
recommendations</article-title>
          <source>Pediatr Dermatol</source>
          <year>2009</year>
          <volume>26</volume>
          <fpage>610</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="pmid">19840322</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manunza</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Syed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Laguda</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Linward</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gholam</surname>
              <given-names>K</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Propranolol for complicated infantile haemangiomas: a case series of
30 infants</article-title>
          <source>Br J Dermatol</source>
          <year>2010</year>
          <volume>162</volume>
          <fpage>466</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="pmid">20055816</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D'Angelo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>RI</given-names>
            </name>
          </person-group>
          <article-title>cAMP-dependent protein kinase inhibits the mitogenic action of
vascular endothelial growth factor and fibroblast growth factor in capillary
endothelial cells by blocking Raf activation </article-title>
          <source> J Cell Biochem</source>
          <year>1997</year>
          <volume>67</volume>
          <fpage>353</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="pmid">9361190</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Della Nina</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>ZN</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Macea</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Presentation, progression and treatment of cutaneous hemangiomas -
Experience of the Outpatients Clinic of Pediatric Dermatology - Hospital das
Cl&#xED;nicas da Universidade de S&#xE3;o Paulo</article-title>
          <source>An Bras Dermatol</source>
          <year>2006</year>
          <volume>81</volume>
          <fpage>323</fpage>
          <lpage>327</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
